MODEL SPOTLIGHT | Hepa 1-6 – A Murine Model of Hepatocellular Carcinoma

  • Hepatocellular carcinoma (HCC) is an aggressive malignancy which has gradually increased in incidence to affect one million people worldwide and is currently the third leading cause of cancer related deaths in the world.
  • Current clinical approaches such as single or combination immunotherapy, monoclonal antibodies, or oncolytic virus therapy have demonstrated tumor shrinkage and improved survival but are not curative.
  • To evaluate novel therapies in a preclinical platform, MI Bioresearch has established the syngeneic HCC model Hepa 1-6.

Read our latest model spotlight on the murine model of hepatocellular carcinoma, Hepa 1-6. See our presentation of in vivo data on tumor model growth kinetics, response to checkpoint inhibitors, and in combination with focal radiation.